Bimekizumab safety and efficacy in patients with psoriatic arthritis: 3-year results from two phase 3 studies - PubMed
3 hours ago
- #psoriatic arthritis
- #bimekizumab
- #long-term efficacy
- Bimekizumab, a monoclonal IgG1 antibody inhibiting IL-17A and IL-17F, demonstrated sustained efficacy and safety in psoriatic arthritis (PsA) patients over 3 years.
- Two phase 3 studies (BE OPTIMAL and BE COMPLETE) evaluated bimekizumab in bDMARD-naïve and TNFi-IR PsA patients, with an open-label extension (BE VITAL).
- Treatment-emergent adverse event rates remained consistent over 3 years, with no new safety signals identified.
- High response rates for efficacy outcomes (ACR50, swollen joint count resolution, PASI 100 improvement) were sustained in both bDMARD-naïve and TNFi-IR patients.
- Bimekizumab is suitable for long-term treatment in PsA patients, regardless of prior treatment history.